TET vs. ZTF, SYNT, ESNT, ELM, VCT, GFM, KMR, FXPO, GGP, and SOLG
Should you be buying Treatt stock or one of its competitors? The main competitors of Treatt include Zotefoams (ZTF), Synthomer (SYNT), Essentra (ESNT), Elementis (ELM), Victrex (VCT), Griffin Mining (GFM), Kenmare Resources (KMR), Ferrexpo (FXPO), Greatland Gold (GGP), and SolGold (SOLG). These companies are all part of the "basic materials" sector.
Zotefoams (LON:ZTF) and Treatt (LON:TET) are both small-cap basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, community ranking, institutional ownership and dividends.
Treatt has a consensus price target of GBX 655, indicating a potential upside of 35.31%. Given Zotefoams' higher possible upside, analysts clearly believe Treatt is more favorable than Zotefoams.
Zotefoams has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Treatt has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.
74.9% of Zotefoams shares are owned by institutional investors. Comparatively, 70.1% of Treatt shares are owned by institutional investors. 18.6% of Zotefoams shares are owned by insiders. Comparatively, 12.3% of Treatt shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Zotefoams pays an annual dividend of GBX 7 per share and has a dividend yield of 1.6%. Treatt pays an annual dividend of GBX 8 per share and has a dividend yield of 1.7%. Zotefoams pays out 3,684.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Treatt pays out 4,444.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Treatt has higher revenue and earnings than Zotefoams. Zotefoams is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks.
Zotefoams received 87 more outperform votes than Treatt when rated by MarketBeat users. Likewise, 69.49% of users gave Zotefoams an outperform vote while only 68.83% of users gave Treatt an outperform vote.
Treatt has a net margin of 7.42% compared to Treatt's net margin of 7.28%. Treatt's return on equity of 8.20% beat Zotefoams' return on equity.
In the previous week, Zotefoams had 1 more articles in the media than Treatt. MarketBeat recorded 1 mentions for Zotefoams and 0 mentions for Treatt. Treatt's average media sentiment score of 0.40 beat Zotefoams' score of 0.00 indicating that Zotefoams is being referred to more favorably in the media.
Summary
Zotefoams beats Treatt on 10 of the 19 factors compared between the two stocks.
Get Treatt News Delivered to You Automatically
Sign up to receive the latest news and ratings for TET and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TET and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
